Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

DERBALA, M.; AL KAABI, S.; EL DWEIK, N.; PASIC, F.; BUTT, M.; YAKOOB, R.; AL-MARRI, A.; AMER, A.; MORAD, N.; Bener, Abdulbari

doi:10.3748/wjg.v12.i35.5692

Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage

DERBALA M. F., AL KAABI S. R., EL DWEIK N. Z., PASIC F., BUTT M. T., YAKOOB R., ...More

WORLD JOURNAL OF GASTROENTEROLOGY, vol.12, no.35, pp.5692-5698, 2006 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 12 Issue: 35
Publication Date: 2006
Doi Number: 10.3748/wjg.v12.i35.5692
Journal Name: WORLD JOURNAL OF GASTROENTEROLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.5692-5698
Istanbul University Affiliated: No

Abstract

AIM: To evaluate pegylated interferon alpha2a (PegIFN-alpha 2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate.